Purchase price was in excess of $220 M US.Īs actingCMO of Eragen, Dr. Ibis was acquired by Abbott and led to development of IBIS TIGER/T5000 Universal Biosensor platform. Cooper designed the physical layoutand personnel requirements for CODIS mass spec laboratory for IBIS Biosciences. NimbleGen was acquired by Roche for $250 Million U.S.ĭr. Cooper built the staff to 20 members located in Iceland. investigators with DNA chips designed uniquely for each investigative purpose. The facility served both European and U.S. Visible Genetics and TRUGENE were subsequently acquired by Bayer for $61.4 Million US.īuilt and managed the NimbleGen microarray technology in Reykjavik, Icelandutilizing photosynthesis chemistry. To commercialize and distribute products in the U.S., he created "The Gene Foundry" as a spinoff which successfully distributed TruGene apparatus and kits throughout the U.S. Cooper has also had a key advisory role in substantial medical devices which resulted in commercially successful products and/or acquisitions by major pharmaceutical and medical technology companies.Īs Senior Medical Advisor to Visible Genetics (Toronto), he oversaw TRUGENE HIV-1 DNA sequencing format which was the first commercial FDA approved sequencing kit to detect HIV resistance. Cooper continues to be active publishing his most recent clinical research in three manuscripts in the international, peer reviewed, open access Journal Clinics in Medicine (ISSN: 2688-6731) in the last year.ĭr. Cooper is the author of more than 100 scientific and medical publications in molecular diagnostics, infectious disease, hematology, cancer, human genetics, pediatrics, precision medicine and the development of novel gene therapies which were supported by numerous grants including grants from the National Institutes of Health, the American Cancer Society and the Department of Defense Breast Cancer Initiative. While at the University of Pittsburgh, he founded the first division of Molecular Pathology in the United States, assisted in founding and served as the first President of the Association for Molecular Pathology (AMP), and was editor and founder of the journal, Molecular Diagnosis - "A journal devoted to the understanding of human disease through the clinical application of molecular biology." His academic honors include the prestigious Lichfield Lectureship, Oxford University, Oxford, England. His original research continues to be highly regarded and regularly referenced as CD44 therapeutics have moved into clinical trials. Cooper's research focused on defining the various isoforms and role of CD44 in tumor metastasis. While Professor of Molecular Pathology at Duke and UPMC, Dr. Cooper has held tenured Pathology faculty positions at Duke University Medical Center and the University of Pittsburgh Medical Center.
of Toronto, Canada, where he assisted with the development of the TRUGENE TM HIV-1 Genotyping Kit, the first FDA approved drug resistance test for routine clinical use. Cooper also served as Senior Scientific Advisor to Visible Genetics, Inc. Cooper established NimbleGen Systems of Iceland, LLC, which manufactured custom DNA arrays and related services to the scientific research marketplace worldwide. Cooper subsequently served as Chief Medical Officer of NimbleGen Systems Inc. Cooper also assisted in opening new markets for Quest Diagnostics in Asia, South America and Europe.ĭr.
QUEST DIAGNOSTICS APPOINTMENTS ISO
Cooper coordinated the Nichols Institute's move for Quest to an ISO 9001 Company, expanded their HIV and Genetic Testing, and reorganized the Nichols Institute Research and Test Development efforts into a clinical specialty focus. The Nichols Institute is also known as one of the premier reference labs in the entire world (Nichols Institute: The Quest Diagnostics Advantage - YouTube)
The Nichols Institute, a wholly-owned division of Quest Diagnostics, is the premier reference lab for Quest Diagnostics. Cooper served originally as the Chief Science Officer and Chief Operating Officer for Quest Diagnostics Nichols Institute and later as Chief Science Officer of Quest Diagnostics (DGX:NYSE). in Chemistry from Florida State University and his M.D. M.D., CEO and Founder of PhytoMedical Solutions, LLC and PhytoDental Solutions, LLC to its scientific advisory panel. (OTC PINK:STEV) ("Stevia Corp" or the "Company"), a healthcare company focused on the commercial development of products that support a healthy lifestyle announced today the appointment of David L.
Quest diagnostics empower login.NEW YORK, NY / ACCESSWIRE / J/ Stevia Corp.
0 kommentar(er)
